Basic Information
Viatris Pharmaceutical Japan, Inc. is a subsidiary of Viatris, Inc. The company is dedicated to the development of cobitolimod for the treatment of ulcerative colitis. Cobitolimod is a TLR9 agonist currently being evaluated in the global Phase III program CONCLUDE as a new approach for treating moderate to severe ulcerative colitis.
Viatris Pharmaceutical Japan, Inc.
Japan
unclear
--
--
--
Enterprise Profile
Industrial Sector
Technology
Concept
Application Scenarios